ADM Board of Directors Enhances R&D, Innovation Expertise with Nomination of Elanco Executive Ellen de Brabander
Retrieved on:
Tuesday, March 14, 2023
Agriculture, Natural Resources, Consumer, Pets, Other Natural Resources, Multimedia, Research, Retirement, Royal Netherlands Chemical Society, NYSE, Massachusetts Institute of Technology, Partnership, Boehringer Ingelheim, DSM, Yves De Brabander, Merck & Co., Schering-Plough, Investment, Leiden University, Animal, Food safety, ADM, Growth, Innovation, Publication, Molecular biology, Doctor of Philosophy, PepsiCo, Central European Institute of Technology, European Institute, Public policy, Management, Elanco
ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced that its Board of Directors has nominated Elanco executive vice president for Innovation and Regulatory Affairs, Dr. Ellen de Brabander, to stand for election to the Board at the company’s upcoming Annual Stockholders’ Meeting on May 4, 2023.
Key Points:
- ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced that its Board of Directors has nominated Elanco executive vice president for Innovation and Regulatory Affairs, Dr. Ellen de Brabander, to stand for election to the Board at the company’s upcoming Annual Stockholders’ Meeting on May 4, 2023.
- De Brabander has also held executive leadership positions in Boehringer Ingelheim (then known as Merial), Merck Animal Health (previously Intervet), and DSM.
- ADM also announced that Lead Director Donald Felsinger will retire from the Board, having reached the retirement age of 75.
- “When Don Felsinger joined our Board of Directors in 2009, ADM was a very different company,” Luciano said.